Skip to main content

Table 3 Statins for the prevention of cardiovascular mortality[17].

From: Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison

Treatment Comparison

Mixed Treatment Comparison

Adjusted Indirect Comparison

 

Odds Ratio

95% Credible Interval

Odds Ratio

95% Confidence Intervals

Atorvastatin vs. Placebo

0.88

(0.69, 1.11)

0.88

(0.70, 1.12)

Fluvastatin vs. Placebo

0.77

(0.53, 1.11)

0.77

(0.53, 1.11)

Pravastatin vs. Placebo

0.91

(0.80, 1.03)

0.91

(0.81, 1.02)

Lovastatin vs. Placebo

0.67

(0.35, 1.24)

0.55

(0.31, 0.99)

Fluvastatin vs. Atorvastatin

0.87

(0.56, 1.35)

0.87

(0.56, 1.35)

Pravastatin vs. Atorvastatin

1.03

(0.79, 1.35)

1.03

(0.79, 1.33)

Lovastatin vs. Atorvastatin

0.76

(0.38, 1.47)

0.62

(0.33, 1.15)

Pravastatin vs. Fluvastatin

1.18

(0.80, 1.75)

1.18

(0.79, 1.74)

Lovastatin vs. Fluvastatin

0.87

(0.41, 1.80)

0.71

(0.36, 1.41)

Lovastatin vs. Pravastatin

0.74

(0.39, 1.38)

0.60

(0.33, 1.08)

  1. Bolded text denotes head-to-head meta-analysis evaluations. * Mixed treatment method identifies a significant effect, adjusted indirect comparison does not, adjusted indirect comparison identifies significant effect, mixed treatment comparison does not. ** Direction of effect differs between approaches, ***Important effect size differences.